• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Do standardised prognostic algorithms reflect local practice? Application of EORTC risk tables for non-muscle invasive (pTa/pT1) bladder cancer recurrence and progression in a local cohort.标准化预后算法是否反映了当地的实际情况?欧洲癌症研究与治疗组织(EORTC)风险表在本地一组非肌层浸润性(pTa/pT1)膀胱癌复发和进展中的应用。
ScientificWorldJournal. 2011 Apr 5;11:751-9. doi: 10.1100/tsw.2011.77.
2
The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables.EORTC 表格高估了卡介苗治疗非肌肉浸润性膀胱癌患者的复发和进展风险:EORTC 风险表格的外部验证。
Eur Urol. 2011 Sep;60(3):423-30. doi: 10.1016/j.eururo.2011.05.033. Epub 2011 May 25.
3
EORTC Risk Model to Predict Progression in Patients With Non-Muscle-Invasive Bladder Cancer: Is It Safe to Use in Clinical Practice?预测非肌层浸润性膀胱癌患者病情进展的欧洲癌症研究与治疗组织(EORTC)风险模型:在临床实践中使用是否安全?
Clin Genitourin Cancer. 2016 Apr;14(2):176-82. doi: 10.1016/j.clgc.2015.09.005. Epub 2015 Sep 25.
4
[Efficacy of European Organization for Research and Treatment of Cancer (EORTC) risk tables for the prediction of recurrence and progression of non-muscle invasive bladder cancer after intravesical pirarubicin instillation].[欧洲癌症研究与治疗组织(EORTC)风险表对吡柔比星膀胱灌注后非肌层浸润性膀胱癌复发和进展的预测效能]
Zhonghua Zhong Liu Za Zhi. 2012 Aug;34(8):609-12. doi: 10.3760/cma.j.issn.0253-3766.2012.08.011.
5
Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system.新型列线图预测原发性非肌肉浸润性膀胱癌的复发和进展:与欧洲癌症研究与治疗组织评分系统相比预测效能的验证。
World J Urol. 2019 Sep;37(9):1867-1877. doi: 10.1007/s00345-018-2581-3. Epub 2018 Dec 10.
6
A Comparison of EORTC And CUETO Risk Tables in Terms of the Prediction of Recurrence and Progression in All Non-Muscle-Invasive Bladder Cancer Patients.在预测所有非肌层浸润性膀胱癌患者复发和进展方面,欧洲癌症研究与治疗组织(EORTC)风险表与CUETO风险表的比较
Urol J. 2019 Feb 21;16(1):37-43. doi: 10.22037/uj.v0i0.4091.
7
Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel.非肌层浸润性膀胱癌的风险分层工具和预后模型:欧洲泌尿外科学会非肌层浸润性膀胱癌指南小组的批判性评估。
Eur Urol Focus. 2020 May 15;6(3):479-489. doi: 10.1016/j.euf.2018.11.005. Epub 2018 Nov 22.
8
Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder.EORTC 风险表和 CUETO 评分模型预测非肌肉浸润性膀胱尿路上皮癌结局的准确性。
Br J Cancer. 2013 Sep 17;109(6):1460-6. doi: 10.1038/bjc.2013.372. Epub 2013 Aug 27.
9
External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non -muscle invasive bladder cancer stages Ta and T1.欧洲癌症研究与治疗组织(EORTC)风险评分对巴西非肌层浸润性膀胱癌Ta和T1期患者经尿道切除术后复发预测的外部验证
Int Braz J Urol. 2016 Sep-Oct;42(5):932-941. doi: 10.1590/S1677-5538.IBJU.2015.0169.
10
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.EORTC 列线图和风险分组用于预测非肌肉浸润性 Ta-T1 期尿路上皮膀胱癌患者接受 1-3 年卡介苗维持治疗后的复发、进展、疾病特异性和总生存情况。
Eur Urol. 2016 Jan;69(1):60-9. doi: 10.1016/j.eururo.2015.06.045. Epub 2015 Jul 23.

引用本文的文献

1
Predicting Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer: Systematic Review on the Performance of Risk Stratification Models.预测非肌层浸润性膀胱癌患者的复发和进展:风险分层模型性能的系统评价
Bladder Cancer. 2022 Dec 14;8(4):339-357. doi: 10.3233/BLC-220055. eCollection 2022.
2
Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): A cohort analysis.EORTC、CUETO 和 EAU 风险分层在预测初发非肌肉浸润性膀胱癌(NMIBC)患者复发、进展和死亡中的验证:队列分析。
Cancer Med. 2020 Jun;9(11):4014-4025. doi: 10.1002/cam4.3007. Epub 2020 Mar 26.
3
Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG's receptor ILT2 on peripheral CD8 T cells.通过检测外周血CD8 T细胞上检查点HLAG的受体ILT2预测非肌层浸润性膀胱癌复发
Oncotarget. 2018 Sep 4;9(69):33160-33169. doi: 10.18632/oncotarget.26036.
4
Applicability of the EORTC risk tables to predict outcomes in non-muscle-invasive bladder cancer in Turkish patients.欧洲癌症研究与治疗组织(EORTC)风险表在预测土耳其非肌层浸润性膀胱癌患者预后中的适用性。
Turk J Urol. 2017 Mar;43(1):48-54. doi: 10.5152/tud.2016.77603. Epub 2017 Jan 6.
5
Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-muscle Invasive Bladder Cancer in Asia.亚洲初发非肌肉浸润性膀胱癌新型复发风险分层的建立和验证。
EBioMedicine. 2016 Oct;12:98-104. doi: 10.1016/j.ebiom.2016.08.051. Epub 2016 Sep 2.
6
External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non -muscle invasive bladder cancer stages Ta and T1.欧洲癌症研究与治疗组织(EORTC)风险评分对巴西非肌层浸润性膀胱癌Ta和T1期患者经尿道切除术后复发预测的外部验证
Int Braz J Urol. 2016 Sep-Oct;42(5):932-941. doi: 10.1590/S1677-5538.IBJU.2015.0169.
7
Selection of adjuvant intravesical therapies using the European Organization for Research and Treatment of Cancer scoring system in patients at intermediate risk of non-muscle-invasive bladder cancer.采用欧洲癌症研究与治疗组织评分系统选择辅助性膀胱内治疗方案治疗非肌层浸润性膀胱癌中危患者。
J Cancer Res Clin Oncol. 2015 Jan;141(1):161-8. doi: 10.1007/s00432-014-1795-z. Epub 2014 Aug 10.
8
EORTC risk tables - their usefulness in the assessment of recurrence and progression risk in non-muscle-invasive bladder cancer in Polish patients.欧洲癌症研究与治疗组织(EORTC)风险表——其在评估波兰患者非肌层浸润性膀胱癌复发和进展风险中的作用
Cent European J Urol. 2013;66(1):14-20. doi: 10.5173/ceju.2013.01.art5. Epub 2013 Apr 26.
9
Who needs numbers more: patients or doctors?
Cent European J Urol. 2013;66(1):8-9. doi: 10.5173/ceju.2013.01.art2.

标准化预后算法是否反映了当地的实际情况?欧洲癌症研究与治疗组织(EORTC)风险表在本地一组非肌层浸润性(pTa/pT1)膀胱癌复发和进展中的应用。

Do standardised prognostic algorithms reflect local practice? Application of EORTC risk tables for non-muscle invasive (pTa/pT1) bladder cancer recurrence and progression in a local cohort.

作者信息

Pillai Rajiv, Wang Duolao, Mayer Erik K, Abel Paul

机构信息

Department of Urology, West Suffolk Hospital, Cambridge University Teaching Hospitals Trust, Suffolk, U.K.

出版信息

ScientificWorldJournal. 2011 Apr 5;11:751-9. doi: 10.1100/tsw.2011.77.

DOI:10.1100/tsw.2011.77
PMID:21479347
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5720000/
Abstract

A risk calculator algorithm to allow prediction of probabilities of 1- and 5-year recurrence and progression rates in individuals with pTa/pT1 bladder cancer has been proposed by the European Organisation for Research and Treatment of Cancer (EORTC) and was incorporated into the European Association of Urology guidelines in 2006. We attempted to validate this algorithm in a cohort of patients with known outcome. Prognostic data were collected from a consecutively presenting cohort of 109 patients with non-muscle invasive (pTa/pT1) transitional cell cancer (TCC) at a single institution between 1983 and 1985. Using the same statistical models as in the EORTC original paper, predicted probabilities of 1- and 5-year recurrence and progression were calculated. Patients were divided into four risk groups for recurrence (Ir-IVr) and progression (Ip-IVp), respectively, using six prognostic criteria. These were then compared to the probabilities predicted in the EORTC algorithm. The predicted 1- and 5-year probabilities of recurrence were significantly higher in the study population as compared to the original EORTC algorithm for all four risk groups. The predicted 1-year probabilities for progression in groups Ip/IIIp and at 5-years for groups Ip/IIp were in accordance with the original algorithm, but were higher for the other progression groups. The concordance for the model of prediction using the study group for recurrence at 1 and 5 years was 62 and 63%, respectively, and for progression was 65 and 67%, respectively. We were unable to validate the proposed algorithm in our group of patients. Although our study has limitations that prevent firm conclusions on the validity of the algorithm, it does expose some of the drawbacks of standardised nomograms when applied to local clinical practice.

摘要

欧洲癌症研究与治疗组织(EORTC)提出了一种风险计算器算法,用于预测pTa/pT1期膀胱癌患者1年和5年复发及进展率的概率,并于2006年被纳入欧洲泌尿外科学会指南。我们试图在一组已知预后的患者中验证该算法。1983年至1985年间,在一家机构连续收集了109例非肌层浸润性(pTa/pT1)移行细胞癌(TCC)患者的预后数据。使用与EORTC原始论文相同的统计模型,计算1年和5年复发及进展的预测概率。使用六个预后标准,将患者分别分为复发(Ir-IVr)和进展(Ip-IVp)的四个风险组。然后将这些结果与EORTC算法预测的概率进行比较。与原始EORTC算法相比,研究人群中所有四个风险组的1年和5年复发预测概率均显著更高。Ip/IIIp组的1年进展预测概率和Ip/IIp组的5年进展预测概率与原始算法一致,但其他进展组的预测概率更高。使用研究组进行1年和5年复发预测模型的一致性分别为62%和63%,进展预测的一致性分别为65%和67%。我们无法在我们的患者组中验证所提出的算法。尽管我们的研究存在局限性,无法就该算法的有效性得出确凿结论,但它确实揭示了标准化列线图应用于当地临床实践时的一些缺点。